Taiho Oncology Company Profile
✉ Email this page to a colleague
What is the competitive landscape for TAIHO ONCOLOGY, and when can generic versions of TAIHO ONCOLOGY drugs launch?
TAIHO ONCOLOGY has two approved drugs.
There are nine US patents protecting TAIHO ONCOLOGY drugs.
There are one hundred and sixty-five patent family members on TAIHO ONCOLOGY drugs in thirty-five countries and twenty supplementary protection certificates in fourteen countries.
Summary for Taiho Oncology
| International Patents: | 165 |
| US Patents: | 9 |
| Tradenames: | 2 |
| Ingredients: | 2 |
| NDAs: | 2 |
Drugs and US Patents for Taiho Oncology
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Taiho Oncology | LONSURF | tipiracil hydrochloride; trifluridine | TABLET;ORAL | 207981-001 | Sep 22, 2015 | AB | RX | Yes | No | 10,960,004 | ⤷ Sign Up | ⤷ Sign Up | |||
| Taiho Oncology | LYTGOBI | futibatinib | TABLET;ORAL | 214801-001 | Sep 30, 2022 | RX | Yes | Yes | 9,108,973 | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Taiho Oncology | LONSURF | tipiracil hydrochloride; trifluridine | TABLET;ORAL | 207981-001 | Sep 22, 2015 | AB | RX | Yes | No | 9,527,833 | ⤷ Sign Up | Y | Y | ⤷ Sign Up | |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Taiho Oncology
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Taiho Oncology | LONSURF | tipiracil hydrochloride; trifluridine | TABLET;ORAL | 207981-001 | Sep 22, 2015 | 5,744,475 | ⤷ Sign Up |
| Taiho Oncology | LONSURF | tipiracil hydrochloride; trifluridine | TABLET;ORAL | 207981-002 | Sep 22, 2015 | 5,744,475 | ⤷ Sign Up |
| Taiho Oncology | LONSURF | tipiracil hydrochloride; trifluridine | TABLET;ORAL | 207981-002 | Sep 22, 2015 | 6,479,500 | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Taiho Oncology Drugs
Supplementary Protection Certificates for Taiho Oncology Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1849470 | 2017C/028 | Belgium | ⤷ Sign Up | PRODUCT NAME: LONSURF - TRIFLURIDINE/TIPIRACIL; AUTHORISATION NUMBER AND DATE: EU/1/16/1096 20160427 |
| 1849470 | 300889 | Netherlands | ⤷ Sign Up | PRODUCT NAME: TRIFLURIDINE IN COMBINATIE MET TIPIRACILHYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/16/1096 20160427 |
| 1849470 | 1790063-0 | Sweden | ⤷ Sign Up | PRODUCT NAME: TRIFLURIDINE IN COMBINATION WITH TIPIRACIL HYDROCHLORIDE; REG. NO/DATE: EU/1/16/1096 20160427 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
